| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 12.4 | 7.6 | 6.4 |
| Other income | 0.1 | 0.1 | 2.8 |
| Total income | 12.4 | 7.7 | 9.3 |
| Profit before exceptional items & tax | 0.1 | 0.5 | 2.8 |
| Profit before tax | 0.1 | 0.5 | 2.8 |
| Net profit | 0.1 | 0.2 | 2.4 |
| Operating margin | 0.8% | 6.5% | 30.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -95.80% |
|---|---|
| Net profit, quarter on quarter | -50.00% |
| Revenue, year on year | +93.80% |
| Operating profit, quarter on quarter | -100.00% |
BSE results filing, NSE: BIOFILCHEM. Figures extracted from the filing.
Biofil Chemicals & Pharmaceuticals Ltd: key numbers
- Share price
- ₹32.44
- Market cap
- ₹52.79 Cr
- Revenue (annual)
- ₹28.40 Cr
- Net profit (annual)
- ₹2.79 Cr
- P/E (TTM)
- 109.0×Sector 50.4×
- Promoter holding
- 46.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biofil Chemicals & Pharmaceuticals Ltd
All →Biofil Chemicals & Pharmaceuticals Management Change
Biofil Chemicals & Pharmaceuticals shareholders approved the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director, despite him exceeding 75 years of age.
Biofil Chemicals & Pharmaceuticals Annual General Meeting
Biofil Chemicals and Pharmaceuticals Limited held its 41st Annual General Meeting on 23rd September 2026. Members transacted routine business, including adoption of financial statements and director re-appointments.
Biofil Chemicals & Pharmaceuticals Q4 FY26 Results: Net Profit ₹0.2 Cr, Up 0.0% YoY
Biofil Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹7.6 Cr (-9.5% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q4 FY26.
- Key figure
- Net profit ₹0.2 Cr · +0.0% YoY